Literature DB >> 6133382

Prevention of rejection of allogeneic bone marrow transplants by NK 1.1 antiserum.

E Lotzová, C A Savary, S B Pollack.   

Abstract

We have studied the effect of in vivo administration of NK 1.1 antiserum on two functions of natural killer (NK) cells: (A) in vitro cytotoxicity of B6 mice to T cell lymphoma, YAC-1, and (B) potential of B6 mice to reject allogeneic BALB/c bone marrow transplants. We demonstrated that a single i.v. injection of 0.4 ml of NK 1.1 antiserum significantly reduced in vitro NK cell cytotoxic potential and concomitantly prevented rejection of allogeneic bone marrow transplants. NK 1.1 antiserum was effective in diminishing both of these functions when injected 2, 6, or 24 hr before transplantation and NK cell assay, but it was ineffective when given 48 hr before transplantation or the NK cell test. As a specificity control, we investigated the effect of specific anti-T-cell-directed monoclonal antibodies, Thy 1.2 and Lyt 2.2, in the same systems. Neither of these antibodies exerted any effect on NK cell cytotoxicity to YAC-1 or rejection of allogeneic bone marrow transplants. These studies indicate that NK cells represent one of the major components of the mechanism of bone marrow graft rejection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133382     DOI: 10.1097/00007890-198305000-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Evidence for differentiation of NK1+ cells into cytotoxic T cells during acute rejection of allogeneic bone marrow grafts.

Authors:  G Dennert; C Knobloch; S Sugawara; B Yankelevich
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

Review 2.  NKG2D in NK and T cell-mediated immunity.

Authors:  Kouetsu Ogasawara; Lewis L Lanier
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

3.  Suppressive role of NK cells in pokeweed mitogen-induced immunoglobulin synthesis: effect of depletion/enrichment of Leu 11b+ cells.

Authors:  P D Mason; A P Weetman; J G Sissons; L K Borysiewicz
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

4.  Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.

Authors:  Kouetsu Ogasawara; Jonathan Benjamin; Rayna Takaki; Joseph H Phillips; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-08-07       Impact factor: 25.606

5.  The rapid rejection of allogeneic lymphocytes by a non-adaptive, cell-mediated mechanism (NK activity).

Authors:  B Rolstad; S Fossum; H Bazin; I Kimber; J Marshall; S M Sparshott; W L Ford
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

6.  A genetic analysis of natural resistance to nonsyngeneic cells: the role of H-2.

Authors:  G A Carlson; B A Taylor; S T Marshall; A H Greenberg
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

7.  Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis.

Authors:  B Rolstad; H B Benestad
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

8.  Depletion of asialo-GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific cytotoxic T cells.

Authors:  K Varkila
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

9.  Unfractionated spleen cells but not natural killer (NK) cells from RFM donors prevent the progression of host-versus-graft disease in murine RFM/(T6 x RFM)F1 chimeras.

Authors:  R C Hard; M R Patel; L M Keller; T J Linna
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

10.  Natural resistance of lethally irradiated F1 hybrid mice to parental marrow grafts is a function of H-2/Hh-restricted effectors.

Authors:  J P Daley; I Nakamura
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.